contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


toleranzia-ab-biostock-tolaranzia-redo-for-klinisk-studie

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.

Toleranzia

Sjukdomen myastenia gravis gör att immunförsvaret attackerar den egna kroppen. Tolaranzia, utvecklar en läkemedelskandidat med potential att inte bara sänka immunförsvarets attack, utan att ...

<div class="abstract"><p>Sjukdomen myastenia gravis gör att immunförsvaret attackerar den egna kroppen. Tolaranzia, utvecklar en läkemedelskandidat med potential att inte bara sänka immunförsvarets attack, utan att få det att återgå till att skydda kroppen. Nu är behandlingen redo att testas på patienter i fas I/II. Hör vd Charlotte Fribert berätta om den kommande studien och teckningsoptionen i Biostock Studio.</p></div><p>Se hela intervjun på&nbsp;biostock.se&nbsp;(<a href="https://www.biostock.se/">https://www.biostock.se/</a>):</p><p><a href="https://www.biostock.se/2024/10/toleranzias-vd-om-utveckling-och-kapitalanskaffning/">https://www.biostock.se/2024/10/toleranzias-vd-om-utveckling-och-kapitalanskaffning/</a></p><p>Detta är ett pressmeddelande från&nbsp;BioStock&nbsp;- Connecting Innovation &amp; Capital.&nbsp;<a href="https://www.biostock.se">https://www.biostock.se</a></p>

Toleranzia AB: BioStock: Tolaranzia redo för klinisk studie

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

What does negative working capital mean and why is it a good thing?

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Stay up to date with our newsletter